How this indication expansion will impact the ability for generic manufacturing of sema I am unsure, but my assumption is that generic sem and GLP-1s will be available long before resmetirom
Clinical trial data [3] demonstrate average body weight reductions exceeding 15% in higher-dose cohorts, accompanied by favorable shifts in markers of leptin, adiponectin, and insulin sensitivity
In most cases, staying on medication while optimizing nutrition is the better choice
Per the company, this is based on a UCLA study of 11,432 adults, measuring 9 biomarkers associated with biological age and mortality risk in research models
GLP-1 receptor agonists, like Ozempic, work by mimicking a hormone that helps your body release its own insulin, prevents the liver from excess glucose production, and slows the rate at which food leaves the stomach, allowing you to feel fuller longer